Bu-Shen-Jian-Pi-Yi-Qi Therapy Prevents Alcohol-Induced Osteoporosis in Rats.
Bu-Shen-Jian-Pi-Yi-Qi therapy, which refers to reinforcing kidney, regulating qi, and invigorating spleen, is a traditional Chinese medicine, and we investigated its efficacy in treatment of alcohol-induced osteoporosis and its underlying mechanism. Forty adult male Sprague-Dawley rats were randomly assigned into alcohol-supplemented group, JIAN-GU-LING (JGL) group, calcium D3 + alfacalcidol group, and sham-treated group. Bone mineral density (BMD), bone mineral content (BMC), and bone biomechanical properties were assessed. Biochemical analyses of serum and urine specimens were detected. Reverse transcription-polymerase chain reaction was used to detect the mRNA level of vitamin D receptor (VDR). There were markedly lower bone metabolic markers and biomechanical properties in alcohol-supplemented group compared with sham-treated group (all P < 0.05). BMD, BMC, 25(OH)D3, and 1,25(OH)2D3 were elevated in JGL group relative to calcium D3 + alfacalcidol group (all P < 0.05). U-Ca/Cr and U-P/Cr in JGL group were higher than those in the calcium D3 + alfacalcidol group (all P < 0.05). VDR mRNA level in the JGL group was elevated markedly in comparison with alcohol + calcium D3 + alfacalcidol group (P < 0.05). Based on our results, Bu-Shen-Jian-Pi-Yi-Qi therapy inhibits bone loss, promotes bone formation, and effectively improves bone metabolism in rats with experimental alcoholic osteoporosis. The disease reversal is evidenced by increased BMD and BMC, improved biomechanical properties, elevated VDR mRNA level, enhanced response sensitivity of 1, 25(OH)2D3, and reduced S-Ca/P.
1Department of Orthopedic and Traumatology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China; 2Clinical Medical School of Heilongjiang University of Chinese Medicine, Harbin, China; 3Department of Orthopedic Surgery, The Fourth Hospital of Harbin of Medical University, Harbin, China; and 4Graduate School of Heilongjiang University of Chinese Medicine, Harbin, China.
Shu-Jun
SJ
Ren
Guo-Li
GL
Xing
Nai-Wu
NW
Hu
Wei-Ming
WM
Xu
Yong-Qi
YQ
Wang
Qing-Ping
QP
Dong
Yi-Chang
YC
Jiang
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000008:administration & dosage; D002762:Cholecalciferol / Q000008:administration & dosage; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D000431:Ethanol / Q000008:administration & dosage / Q000009:adverse effects*; D006887:Hydroxycholecalciferols / Q000494:pharmacology; D008297:Male; D008516:Medicine, Chinese Traditional / Q000379:methods*; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control*; D019413:Qi; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018167:Receptors, Calcitriol / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
D004365:Drugs, Chinese Herbal; D006887:Hydroxycholecalciferols; D012333:RNA, Messenger; D018167:Receptors, Calcitriol; D002762:Cholecalciferol; D000431:Ethanol; D002118:Calcium; C008088:alfacalcidol